RaySight Medical Secures RMB 50 Million Series A+ Financing Led by China Growth Capital to Advance Cardiovascular AI Diagnostics

China Venture June 5 News: Recently, RaysightMed, an AI-driven healthcare company specializing in cardiovascular care, announced the completion of its RMB 50 million Series A+ financing round. The round was led by China Growth Capital, with participation from Matrix Partners China and Shanghai Greenriver Investment Co., Ltd. In less than two years, RaysightMed has secured three rounds of funding totaling over RMB 100 million. According to reports, the proceeds from this round will primarily be used to accelerate the clinical application and implementation of its core products, strengthen the research and development of other products within its platform, and build out the company’s marketing and service systems.

Dr. Zheng Lingxiao, Founder and CEO of RaysightMed, stated: “CT-FFR, along with otherArtificial IntelligenceOur product is fundamentally different. While other products merely provide information that physicians can already extract from medical images, CT-FFR delivers additional, higher-value insights that are not directly obtainable from imaging alone. The large-scale clinical application of FFR, a functional assessment tool, in the field of cardiovascular and cerebrovascular diseases has become a clear trend, with strong indicators across all sectors. Clinical experts increasingly recognize and emphasize the importance of functional FFR testing. Internationally, HeartFlow has been actively advancing FFRCT technology, while domestically, various new FFR technologies are emerging rapidly. RaysightMed is deeply rooted in the cardiovascular and cerebrovascular fields, committed to providing physicians with high-quality medical services to ensure the earliest diagnosis and most precise treatment for every vessel. Currently, in China’s CT-FFR market, there is no traditional multinational corporation leading market education and promotion. Nevertheless, RaysightMed remains confident in its strategic judgment and capabilities, working alongside industry partners who share this vision to vigorously promote the clinical adoption of CT-FFR as a premium solution in China.

Xiong Weiming, Partner at China Growth Capital and the lead investor in this round, stated, “The effective integration of technologies from IT, physics, and chemical engineering with traditional biomedical application scenarios has always been a key focus for China Growth Capital. We are delighted to join and support the rapid development of RaysightMed, driven by its innovative products deeply aligned with clinical needs, its outstanding team with profound expertise and complementary capabilities, its efficient execution, and its commitment to contributing to national public health. We also look forward to RaysightMed achieving its goal of becoming a platform-based intelligent diagnosis and treatment company in the cardiovascular and cerebrovascular fields at an early date.”

In terms of the team, the three founders of RaysightMed—Zheng Lingxiao, Lan Hongzhi, and Ma Jun—are all returnees with Ph.D. degrees from prestigious U.S. universities. Prior to returning to China, they were affiliated with Johns Hopkins University, Stanford University, Dassault Systèmes, and the da Vinci Surgical System.Robot...and other institutions, with years of dedicated research and work in fields such as medical imaging and fluid dynamics.

Over the past two years, RaysightMed has assembled a PhD- and Master’s-level R&D team with innovation as its core value, accounting for 50% of the company’s total workforce. The team comprises returnee PhDs and Master’s graduates from top global institutions such as Stanford University, Johns Hopkins University, Rensselaer Polytechnic Institute (RPI), Tulane University, the University of Michigan, and the University of Bern, as well as high-caliber talent from leading domestic universities including Tsinghua University, Wuhan University, Beihang University, and Shenzhen University. Meanwhile, the RaysightMed business team consists entirely of professionals from top multinational corporations with over ten years of deep expertise in the cardiovascular field, bringing extensive experience in clinical promotion. Their professionalism will comprehensively accelerate the market adoption and practical application of this technology.